Skip to main content

Table 2 Primary and secondary outcomes of the whole study population

From: Are IgM-enriched immunoglobulins an effective adjuvant in septic VLBW infants?

IgM-eIVIG

Treated

Untreated

  
 

n = 40

n = 39

OR (95%CI)

p

Short term mortality

9 (22%)

18 (46%)

0.16 (0.3-0.7)

0,005*

Total mortality

17 (44%)

18 (46%)

0.46 (0.9-1.8)

NS

IVH

9 (22%)

8 (20%)

1.17 (0.5-2.7)

NS

PVL

3 (7,5%)

2 (3%)

2.6 (0.5-14)

NS

NEC

2 (6%)

1 (3%)

2 (0.4-11)

NS

BDP

4(10%)

4 (10%)

0.97(0.2-4.2)

NS

  1. *p < 0.05 (IVH: intraventricular hemorrhage, PVL: periventricular leukomalacia, NEC: necrotizing enterocolitis, BPD: bronchopulmonary dysplasia).